The FINANCIAL — Roche announced on June 23 that the US Food and Drug Administration (FDA) approved Rituxan Hycela (rituximab and hyaluronidase human) for subcutaneous (under the skin) injection, for ...

SHANGHAI, Nov. 6, 2019 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK), a leading biopharmaceutical company in China focusing on oncology and autoimmune diseases, won the award of "Biosimilar ...

(HealthDay)—Rituxan (rituximab) injection was granted the first approval for a drug to treat granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) in combination with ...

JERUSALEM & PARSIPPANY, N.J. & INCHEON, South Korea--(BUSINESS WIRE)-- Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE ...

Efficacy and safety of zandelisib administered by intermittent dosing (ID) in patients with relapsed or refractory (R/R) follicular lymphoma (FL): Primary analysis of the global phase 2 study TIDAL.

Please provide your email address to receive an email when new articles are posted on . The FDA has approved intravenous Rituxan for the treatment of granulomatosis with polyangiitis and microscopic ...

A subcutaneous formulation of rituximab (MabThera, Roche) could soon be available in Europe, now that the Committee for Medicinal Products for Human Use (CHMP) has recommend the product for approval ...

The combination of Calquence and Rituxan may also be useful during the COVID-19 pandemic as it decreases infusion times and patient interactions, according to an expert. Calquence (acalabrutinib) and ...

Feeding the Controversy: When Pelvic Irradiation Improves Outcomes in High-Risk and Very High-Risk Prostate Cancer The prognosis of elderly patients with diffuse large B-cell lymphoma (DLBCL) is worse ...

Studies presented at the American Society of Ophthalmic Plastic & Reconstructive Surgery 2021 Fall Scientific Symposium explored the impact of lower dose rituximab on orbital lymphoma and factors ...